Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to start review
Explore by Goal
"Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less."
This study profiles FFPE kidney proteomes from 7 steroid-sensitive vs 11 steroid-resistant children with FSGS, finds 302 up and 23 down differentially expressed proteins (FCβ₯2, P<0.05), and highlights enrichment in complement activation and lysosome pathways, with immunohistochemistry validation for LAMP1 (glomerulus) and ACSL4 (tubular epithelium).
Key evidence comes from their LC-MS/MS + MaxQuant/DAVID/STRING workflow and orthogonal IHC validation in human tissue and an LPS mouse nephropathy model.
Primary source:
Long Answer
Paper Review (Science-first, skeptical, evidence-based)
Target question this paper addresses: which proteomic programs in pediatric FSGS kidney tissue differ between steroid-sensitive (SS) and steroid-resistant (SR) cases, and can any candidates be validated?
1) Study design & data generating pipeline (what was actually measured)
Cohort: 18 biopsy-proven pediatric FSGS patients: 7 SS and 11 SR (sex: 16M/2F). Baseline lab/clinical variables reportedly show no significant between-group differences (Table 1).
Specimen type: FFPE kidney biopsies (10 ΞΌm sections) processed via deparaffinization, reduction/alkylation chemistry (TCEP buffer with phosphine reagents), and overnight trypsin digestion.
Proteomics platform: LC-MS/MS on Q Exactive HF-X with EASY-nLC 1200; MS1 full scan at high resolution, DDA MS2 with HCD.
Identification/quantification: MaxQuant v1.5.3.30 with Andromeda search against human RefSeq; reported FDR <1% at peptide and protein levels; iBAQ for quant; match-between-runs; iFOT normalization.
Enrichment & networks: DAVID v6.7 for GO/KEGG enrichment; STRING for PPI; Cytoscape/ cytoHubba to select top hub genes.
Orthogonal validation: Immunohistochemistry for LAMP1 and ACSL4 in human SR tissues and a C57BL/6 LPS-induced nephropathy model (6 mice per group).
2) Quantitative summary plots (from reported counts, not conjecture)
Reported group counts: 7 SS vs 11 SR (n=18 total).
The paper reports final DEPs between SR and SS with fold change β₯2 and P<0.05: 302 up and 23 down (note: earlier in Results it also mentions 325 DEPs; see limitations section for why that mismatch/wording should be treated cautiously).
Paper states LAMP1 accumulation higher in glomeruli and ACSL4 higher in tubular epithelial cells, validated in human SR and in LPS mouse nephropathy.
3) Pathway-level claims: complement and lysosome (and what could bias them)
Reported enrichment highlights
GO (BP): upregulated proteins enriched for protein transport, regulation of complement activation, cytolysis, and actin cytoskeleton reorganization.
KEGG: upregulated proteins enriched in complement pathway (7 pathways; p-value 0.0026) and lysosome pathway (7 pathways; p-value 0.036).
Skeptical interpretation: pathway enrichment is a statistical over-representation of annotated terms among differentially expressed proteins, not direct proof of causal biology. GO/KEGG/DAVID enrichment can be sensitive to list size, annotation coverage, and multiple-testing correction choicesβdetails are not fully enumerated in the provided text.
The paperβs complement emphasis is consistent with prior reports of complement activation in FSGS and broader kidney disease contexts. For example, a study reports complement activation in patients with focal segmental glomerulosclerosis.
Lysosome/proteolysis dysregulation can plausibly connect to kidney injury phenotypes; the paper cites a prior proteomic study of individual glomeruli in FSGS mutation-associated contexts showing elevation of LAMP1 and dyregulation of proteolysis.
Important limitation: plausibility β causality. Without longitudinal patient outcomes tied to proteomic markers, or functional experiments showing that modulating complement/lysosome changes steroid resistance, the present data remain correlational.
5) Methodological red flags & bias checks (what could mislead the biology)
Small sample size (n=18) + multiple comparisons: proteomics quantifies thousands of proteins; even with FDR and fold-change filters, the probability of false positives can remain elevated without replication/panel validation and stringent multiple-testing correction reporting. The authors acknowledge retrospective, small sample size constraints.
Potential treatment confounding prior to biopsy: the paper states it cannot eliminate effects of steroid or calcineurin inhibitors (CNIs) before biopsy. That matters because therapy could alter proteomic abundance independent of intrinsic steroid resistance.
FFPE extraction/processing bias: FFPE processing (fixation, crosslinking, variable recovery) can bias which proteins are detectable and which are quantified. While extraction+MS can work, it is a known technical source of systematic differences.
Text inconsistency to reconcile: the abstract states 325 DEPs (foldchange β₯2, P<0.05), while Results state 302 up and 23 down (sum=325) after reprocessingβthis may be consistent arithmetically, but readers should confirm whether any additional filters are applied and how many DEPs are ultimately carried forward into downstream analyses.
Enrichment statistical assumptions: DAVID GO/KEGG enrichment depends on annotation coverage, background selection, and multiple-testing strategies; the provided text does not detail how multiple testing is handled.
6) What would change my mind? (disproving or narrowing interpretations)
The central interpretive claim is: proteomic complement/lysosome programs and two candidates (LAMP1, ACSL4) associate with steroid resistance. Disconfirming outcomes would include:
Independent cohorts (new patients, ideally multi-center) failing to reproduce differential abundance of LAMP1 and/or ACSL4 between SS and SR.
Evidence that LAMP1/ACSL4 signals are driven primarily by confounding treatment exposure rather than intrinsic SR phenotype (e.g., proteomics stratified by pre-biopsy steroid/CNI exposure).
Functional studies demonstrating that altering lysosome/complement-related proteins changes injury but not steroid responsiveness in models of FSGS steroid resistance (i.e., specificity for steroid resistance rather than general injury). (No direct functional specificity test is presented in the provided textβso this remains an open uncertainty.)
7) Data availability & reproducibility signals
The paper reports depositing mass spectrometry proteomics data to ProteomeXchange via PRIDE with dataset identifier PXD036164. This supports reproducibility of the raw-to-processed identification steps, at least for those who can replicate the exact pipelines.
8) Author reviews (bespoke BGPT links)
Feedback:
Updated: April 27, 2026
BGPT Paper Review
Study Novelty
60%
FFPE tissue LC-MS/MS comparisons for pediatric FSGS steroid response are a plausible extension of existing proteomics directions; the novelty here is mainly in the particular steroid-response contrast and the two-candidate validation (LAMP1/ACSL4) rather than an entirely new technology or conceptual framework.
Scientific Quality
60%
Strengths: clear multi-step workflow; explicit LC-MS/MS and MaxQuant-based quantification; use of GO/KEGG and PPI/hub genes; orthogonal IHC validation in human and an LPS mouse injury model; and PRIDE deposition (PXD036164). Red flags: very small cohort size (n=18) with thousands of proteins; retrospective design with possible prior steroid/CNI exposure confounding; FFPE technical bias risk; and enrichment analyses rely on annotation statistics that are sensitive to multiple testing choices (not fully specified in the provided text).
Study Generality
50%
The study is focused on pediatric primary FSGS steroid response using FFPE renal biopsies, so generality to other nephrotic syndromes/age groups or to causal mechanisms is limited without broader validation. The pathway themes (complement/lysosome) are broadly relevant, but the specific candidates require replication.
Study Usefulness
60%
Useful as a candidate-generating resource with orthogonal IHC support for LAMP1/ACSL4 and a mechanistic direction (complement/lysosome) consistent with prior FSGS complement evidence; less useful for immediate clinical prediction because independent validation and longitudinal outcome performance are not shown.
Study Reproducibility
70%
Reproducibility is helped by detailed MS acquisition parameters, MaxQuant-based processing, and PRIDE deposition (PXD036164). However, FFPE sample preparation variability and lack of full downstream statistical/multiple-testing details in the provided text reduce reproducibility confidence.
Explanatory Depth
60%
The paper offers pathway-level associations and candidate localization (IHC in human and LPS mouse), but does not demonstrate causal mechanisms linking complement/lysosome biology to steroid resistance specifically. Therefore mechanistic explanatory depth is moderate.
It is loading the reported cohort and DEP-count summaries, generating Plotly visuals for SS vs SR counts and SR up/down DEP bar charts, then outputs a figure dashboard for rapid paper-level inspection.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
βACSL4 is simply a cancer-like marker of generic tissue stress.β This becomes less plausible if ACSL4 remains SR-associated after controlling for injury severity and if broader lysosome/complement signatures co-vary in independent cohorts; the current study cannot fully exclude treatment/injury confounding.
βComplement pathway enrichment implies complement is the sole driver of SR.β This is unlikely because enrichment is not causality and because other pathways (protein transport/cytoskeleton/actin remodeling) are also enriched; without functional perturbation linked to steroid response, complement may be one component among several.
Explore by Goal
Quick Answer
Long Answer
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion